Request Deal Involvement
Teoxane to acquire the remaining shares in Revance Therapeutics at a $375m valuation.
Identify your role
Select the side you represented in this transaction, and provide your current job title.
Service Providers
legal advisors
Walder Wyss
legal advisors
Davis Polk & Wardwell
pr advisors
Collected Strategies
financial advisors
Jefferies & Company
financial advisors
Centerview Partners
legal advisors
Skadden Arps Slate Meagher & Flom
pr advisors
FGS Global
or
Principals
bidder
TEOXANE SA
target
REVANCE THERAPEUTICS INC
Principals or Service Provider not listed?Add missing Service Provider or Principal
Enter your Job Title on this deal
This title will appear on your profile next to this deal involvement.
To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:
All rights reserved. Copyright © 2025 Datasite